[Chancellor’s Professor] Daniel Gillen from the University of California at Irvine said with a limited efficacy and safety data set from the small study, there isn’t enough information to provide an answer about the risk-benefit profile. Gillen also said there is not a “full understanding of the mechanism of action” of sabizabulin, which gave him pause.
FDA Adcomm votes against Veru’s COVID-19 therapeutic
Biospace, Nov. 10, 2022
November 10, 2022